MADRIGAL PHARMACEUTICALS, INC. Payments to Acquire Debt Securities, Available-for-sale
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Payments to Acquire Debt Securities, Available-for-sale of $306.68 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-07-30
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $148.85M, a 34.00% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $157.83M, a 20.65% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $212.96M, a 39.19% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $478.21M, a 14.94% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $1.05B, a 7.40% decline from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $1.13B, a 35.56% increase from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $834.44M, a 481.58% increase from fiscal 2022.
- MADRIGAL PHARMACEUTICALS, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $143.48M, a 63.60% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $148.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $306.68M 10-Q · filed 2026-07-30 | $519.63M derived: sum of 3 quarters · filed 2026-07-30 | $997.84M derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | $157.83M 10-Q · filed 2026-05-06 | $370.79M derived: sum of 2 quarters · filed 2026-05-06 | $848.99M derived: sum of 3 quarters · filed 2026-05-06 | $1.07B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-12-31 | $212.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $691.16M derived: sum of 2 quarters · filed 2026-02-19 | $916.70M derived: sum of 3 quarters · filed 2026-07-30 | $1.05B 10-K · filed 2026-02-19 |
| 2025-09-30 | $478.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $703.74M derived: sum of 2 quarters · filed 2026-07-30 | $834.55M 10-Q · filed 2025-11-04 | $1.18B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-06-30 | $225.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | $356.35M 10-Q · filed 2026-07-30 | $706.53M derived: sum of 3 quarters · filed 2026-07-30 | $1.12B derived: sum of 4 quarters · filed 2026-07-30 |
| 2025-03-31 | $130.81M 10-Q · filed 2026-05-06 | $481.00M derived: sum of 2 quarters · filed 2026-05-06 | $897.03M derived: sum of 3 quarters · filed 2026-05-06 | $1.18B derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $350.19M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $766.22M derived: sum of 2 quarters · filed 2026-02-19 | $1.05B derived: sum of 3 quarters · filed 2026-02-19 | $1.13B 10-K · filed 2026-02-19 |
| 2024-09-30 | $416.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $696.82M derived: sum of 2 quarters · filed 2025-11-04 | $781.02M 10-Q · filed 2025-11-04 | $1.26B derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $280.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $364.99M 10-Q · filed 2025-08-05 | $839.88M derived: sum of 3 quarters · filed 2026-02-19 | $908.73M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $84.20M 10-Q · filed 2025-05-01 | $559.09M derived: sum of 2 quarters · filed 2026-02-19 | $627.94M derived: sum of 3 quarters · filed 2026-02-19 | $719.81M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $474.89M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $543.74M derived: sum of 2 quarters · filed 2026-02-19 | $635.62M derived: sum of 3 quarters · filed 2026-02-19 | $834.44M 10-K · filed 2026-02-19 |
| 2023-09-30 | $68.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $160.73M derived: sum of 2 quarters · filed 2024-10-31 | $359.55M 10-Q · filed 2024-10-31 | |
| 2023-06-30 | $91.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $290.70M 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | $198.82M 10-Q · filed 2024-05-07 | |||
| 2022-12-31 | $143.48M 10-K · filed 2025-02-26 | |||
| 2021-12-31 | $394.12M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |